Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 2, 2012, Pages 305-313

  Tolcher, A W ^a   Chi, K N ^b   Shore, N D ^c   Pili, R ^d   Molina, A ^e   Acharya, M ^e   Kheoh, T ^e   Jiao, J J ^e   Gonzalez, M ^e   Trinh, A ^e   Pankras, C ^b   Tran, N ^e  

^a Center for Cancer Care   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Carolina Urologic Research Center   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Abiraterone acetate; Castration resistant prostate cancer; Pharmacokinetics; Phase 1; QT interval

Indexed keywords

ABIRATERONE ACETATE; PREDNISONE;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOOD SAMPLING; CANCER PAIN; CANCER PATIENT; CARDIOVASCULAR PARAMETERS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY MONITORING; FATIGUE; HEART RATE; HEMATOLOGIC DISEASE; HOLTER MONITORING; HOT FLUSH; HUMAN; HYPOKALEMIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MUSCLE SPASM; NAUSEA; OPEN STUDY; PERIPHERAL SENSORY NEUROPATHY; PHASE 1 CLINICAL TRIAL; PR INTERVAL; PRIORITY JOURNAL; QRS DURATION; QT INTERVAL; QT PROLONGATION; SENSORY NEUROPATHY; SIDE EFFECT; SINUS BRADYCARDIA; SINUS TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANDROGENS; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PREDNISONE; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84866525758     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1916-9     Document Type: Article

References (17)

1. Yap TA, Carden CP, Attard G, de Bono JS (2008) Targeting CYP17: Established and novel approaches in prostate cancer. Curr Opin Pharmacol 8:449-457
2. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571
3. Bianchini D, Zivi A, Sandhu S, de Bono JS (2010) Horizon scanning for novel therapeutics for the treatment of prostate cancer. Ann Oncol 21 Suppl 7:vii43-vii55
4. Chan FC, Potter GA, Barrie SE, Haynes BP, Rowlands MG, Houghton J, Jarman M (1996) 3-and 4-pyridylalkyl adamantanecarboxylates: Inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J Med Chem 39:3319-3323
5. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M (1994) Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50:267-273
6. O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M (2004) Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90:2317-2325
7. ZYTIGA-PI (2011) ZYTIGA-Prescribing Information http://www.zytiga.com/ pdf/prescribing-information.pdf. April 2011. Accessed on 18 July 2011
8. Health Canada (2011) Health Canada, product information. http://webprod3.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang= eng. Accessed on 22 Nov 2011
9. European Medicines Agency (2011) Assessment report for ZYTIGA. Procedure No.: EMEA/H/C/002321. http://www.ema. europa.eu/docs/en-GB/document-library/ EPAR-Public-assessment-report/human/002321/WC500112860.pdf. Accessed 22 Nov 2011
10. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
12. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
13. Shah RR (2002) The significance of QT interval in drug development. Br J Clin Pharmacol 54:188-202
14. ICH (2005) International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: E14. http://www.ich.org/LOB/media/MEDIA1476.pdf.12. May 2005. Accessed on 21 Jan 2011
15. Funck-Brentano C, Jaillon P (1993) Rate-corrected QT interval: Techniques and limitations. Am J Cardiol 72:17B-22B
16. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28:1496-1501
17. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005